CELLDEX THERAPEUTICS, INC.
Last · NASDAQ$27.84-0.415 (-1.47%)close · yahoo · 8h ago
Market cap$2.19B78.5M sh
P/E · TTM-6.4fwd -6.6 · eps -4.35 · loss
Beta0.90vs S&P 500
Div yield0.00%annual · TTM
52w range
$22.10$45.14
Volume1.0Msession
Loading chart…
OpenFilings analyst
Our analyst
From latest 10-K · 2026-02-25
- Sbc Revenue High
- Operating Cf Burn
- Net Margin Sharply Negative
- Cash Conversion Weak
- Cash Runway Low
- Accumulated Deficit High
- Rd Intensity High
Red flags
- Sbc Revenue High — SBC/Revenue 2344.1%
- Operating Cf Burn — Negative operating cash flow
- Net Margin Sharply Negative — Net margin -16748.0%
- Cash Conversion Weak — Cash conversion (CFO/Rev) -13653.4%
- Cash Runway Low — Cash runway ~0.1 years
- Accumulated Deficit High — Accumulated deficit / equity 344%
- Rd Intensity High — R&D/Revenue 15862.4%
Upcoming earnings
9:00 PM UTC+1
Period
Sep 2026
Est. EPS
−$1.01
Est. revenue
883,220
Press & signals
- GlobeNewswire
Celldex Reports Second Quarter Financial Results and Provides Corporate Update
- GlobeNewswire
Celldex Announces Planned Transition of Chief Financial Officer
Documents
FormReporting forFiledFlags